Candel Therapeutics (CADL) Share-based Compensation (2020 - 2023)
Historic Share-based Compensation for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $939000.0.
- Candel Therapeutics' Share-based Compensation rose 4810.73% to $939000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.1 million, marking a year-over-year increase of 3398.35%. This contributed to the annual value of $5.3 million for FY2024, which is 7185.38% up from last year.
- As of Q4 2023, Candel Therapeutics' Share-based Compensation stood at $939000.0, which was up 4810.73% from $686000.0 recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Share-based Compensation ranged from a high of $1.9 million in Q3 2021 and a low of -$446000.0 during Q4 2021
- Its 4-year average for Share-based Compensation is $700000.0, with a median of $686000.0 in 2023.
- The largest annual percentage gain for Candel Therapeutics' Share-based Compensation in the last 5 years was 220000.0% (2021), contrasted with its biggest fall of 12544.21% (2021).
- Quarter analysis of 4 years shows Candel Therapeutics' Share-based Compensation stood at $1.8 million in 2020, then plummeted by 125.44% to -$446000.0 in 2021, then soared by 242.15% to $634000.0 in 2022, then surged by 48.11% to $939000.0 in 2023.
- Its last three reported values are $939000.0 in Q4 2023, $686000.0 for Q3 2023, and $733000.0 during Q2 2023.